QingSong Health Corporation
轻松健康集团
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2661)

VOLUNTARY ANNOUNCEMENT MEMORANDUM OF UNDERSTANDING ON STRATEGIC COOPERATION WITH BMGL

This announcement is voluntarily made by QingSong Health Corporation (the "**Company**", together with its subsidiaries, the "**Group**") for the purpose of providing the shareholders and potential investors of the Company with information on the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, on 10 June 2026, the Company and Basel Medical Group Ltd (巴塞爾醫療集團有限公司) ("**BMGL**", stock code on the Nasdaq Stock Exchange: BMGL), after amicable negotiations, entered into a strategic cooperation memorandum (the "**MOU**") with a term of three years. This cooperation is carried out by leveraging the strengths of the Group's self-developed QSevidence (證元芳) • MedClaw medical AI consortium system and AIcare technology stack, together with its years of experience in AI health sectors, and aims to achieve a two-way development of technology output and technology iteration.

Principal terms of the MOU are summarised below:

Date: 10 June 2026 (after trading hours)

Parties: (i) the Company, a digital health enterprise listed on The Stock Exchange of Hong Kong Limited, with core self-developed AIcare technology stack with evidence-based medicine as the core and QSevidence (證元芳) • MedClaw Consortium, and operational experience accumulated in the health insurance value chain;

(ii) BMGL, a medical services group listed on the Nasdaq in the United States and headquartered in Singapore, with clinical competencies across specialist areas including orthopedics, trauma, sports medicine and neurosurgery, and a corporate client network in Southeast Asia built over more than two decades;

Both parties are of the view that combining the Group's proven healthcare AI infrastructure with BMGL's clinical settings and market access in Southeast Asia will help drive the intelligent upgrade of regional healthcare services and jointly explore new market opportunities for both parties.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, as at the date of this announcement, BMGL and its ultimate beneficial owners are third parties independent of and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")).

The parties intend to leverage the Group's AIcare technology stack as a foundation to support BMGL in carrying out AI-native medical services upgrades in the Southeast Asia region, jointly expand the regional market, and establish a long-term and stable strategic partnership. The parties have preliminarily determined to carry out cooperation in the following areas:

(I) Operational Level: Enhancing the Intelligence of BMGL's Existing Business

1. Physician Training: Leveraging evidence-based medicine capabilities to provide sustainable AI clinical decision support and training for BMGL's clinical teams;

2. Patient Customer Services: Optimizing the full-process service experience of patients from appointment and consultation to follow-up through conversational AI;

3. Insurance Claims: Applying AI to claims processing and underwriting judgments to raise the evidence-based standard across the insurance value chain, with particular focus on serving BMGL's clients in industries characterised by high occupational health exposure, such as construction, maritime, and oil and gas.

(II) Growth Level: Jointly Exploring New Markets

1. Cross-Border Health Services: Drawing upon the Group's cross-border health service capabilities and BMGL's regional hub position in Singapore to jointly establish a health services corridor linking China with the specialist networks across Southeast Asia.

Based on the above, the Board is of the view that the entering into of this MOU represents not only a significant step in the overseas application scenarios exploration of the Group's core AI agent technology, but is also conducive to the Group's continued promotion of technological iteration and upgrading as well as the potential business opportunity expansion by leveraging the diversified clinical and service settings in Southeast Asia, further improving the Group's technological capabilities in the field of medical AI, which is aligned with the Group's long-term technology and business development strategies and is in the interests of the Company and its shareholders as a whole.

Save for provisions such as confidentiality, this MOU merely expresses cooperation intention of both parties and does not constitute any legally binding commitment or obligation on either party. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
QingSong Health Corporation
轻松健康集团
YANG Yin
Chairlady of the Board, Executive Director
and Chief Executive Officer

Hong Kong, 10 June 2026

As of the date of this announcement, the Board of the Company comprises: (i) Ms. YANG Yin as executive Director; (ii) Mr. ZHAO Yuping, Mr. ZHENG Kaihuan and Mr. WU Bin as non-executive Directors; and (iii) Dr. WANG Xiaoyan, Mr. CHOW Yiu Ming and Ms. JI Wenting as independent non-executive Directors.